Banco Santander S.A. increased its stake in DexCom, Inc. by 28.9% in the third quarter, acquiring an additional 56,062 shares to hold a total of 250,310 shares valued at approximately $16.84 million. DexCom reported strong Q4 results, exceeding revenue and EPS expectations, with institutional investors collectively owning about 97.75% of the company’s stock. Analysts currently rate DexCom with a consensus “Moderate Buy” and a target price of $85.18.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
DexCom, Inc. $DXCM Shares Purchased by Banco Santander S.A.
Banco Santander S.A. increased its stake in DexCom, Inc. by 28.9% in the third quarter, acquiring an additional 56,062 shares to hold a total of 250,310 shares valued at approximately $16.84 million. DexCom reported strong Q4 results, exceeding revenue and EPS expectations, with institutional investors collectively owning about 97.75% of the company’s stock. Analysts currently rate DexCom with a consensus “Moderate Buy” and a target price of $85.18.